NCT07403552PHASE1RecruitingAccepts Healthy Volunteers
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
Ensho Therapeutics, Inc.
Start Date
1/31/2026
Completion Date
6/1/2026
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Participants (males and females) at least 18 years of age
* Ability to provide written informed consent
* In good heath as determined by medical evaluation,
* Willing and able to comply with trial restrictions, procedures, and requirements
Exclusion Criteria:
* Known sensitivity to any components of the IMP
* History of relevant drug hypersensitivity
* Presents or has a history of clinically significant diseases
* History of difficulty swallowing tablets or capsules.
* Any physical examination findings or medical history that might place the participant at an unacceptable risk for participation in this trial.
Interventions
DRUG
NSHO-101
Conditions
Healthy
Locations
Cenexel Anaheim CA
Anaheim, California 92801
United States